| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2027 ( Subtotal = $0 ) |
| | 2027 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K08CA266937 | Integrating pain-CBT into an mHealth analgesic support intervention for patients withchronic pain from advanced cancers | 000 | 6 | NIH | 10/22/2026 | $0 |
| | 2027 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA293092 | Harnessing naturally occurring cell type-specific regulatory elements and normal HSC hematopoiesis to develop cell lineage-controlled CAR expression and continuously renewing CAR NK cells | 000 | 2 | NIH | 10/22/2026 | $0 |
| | 2027 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R21CA289134 | MUC1-C is a target for advancing immunotherapy of non-small cell lung cancer | 000 | 1 | NIH | 10/14/2026 | $0 |
|
| Issue Date FY: 2026 ( Subtotal = $168,181,606 ) (Continued on the next page) |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R13CA322631 | Bioconductor Conference: Expanding Training, Mentorship, and Collaboration in Genomic Data Science | 000 | 1 | NIH | 8/6/2026 | $75,000 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | P50CA298970 | SPORE in Leukemia | 000 | 1 | NIH | 8/12/2026 | $2,433,959 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R33CA302616 | Gene delivery to antigen-specific T cells via targeted retroviral vectors to treat cancer | 000 | 1 | NIH | 8/17/2026 | $432,050 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA316481 | TRIM28 Inhibition as a Synthetic Lethal Strategy for Small Cell Lung Cancers with NOTCH2-Inactivation | 000 | 1 | NIH | 8/24/2026 | $609,130 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R21CA307422 | Reprogramming tumor-associated macrophages with theranostic nanoparticles | 000 | 1 | NIH | 7/6/2026 | $454,109 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA307360 | Therapeutic vulnerabilities of ARID1A-mutant and -wildtype ovarian clear cell carcinoma | 000 | 1 | NIH | 8/20/2026 | $528,099 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K08CA300940 | The biology and phenotypic consequences of B-cell clonality driven by mosaic chromosomal alterations | 000 | 1 | NIH | 4/27/2026 | $235,491 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA315392 | Structural and mechanistic studies of the RAS/RAF MAPkinase pathway | 000 | 1 | NIH | 8/27/2026 | $657,443 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA301574 | TIRR/53BP1 complex regulates mitotic fidelity and immune-mediated radiation response | 000 | 1 | NIH | 3/24/2026 | $683,075 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R37CA304011 | Prospective Dynamic BH3 Profiling for Clinical Use in Relapsed or Refractory AML | 000 | 1 | NIH | 9/1/2026 | $388,616 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | DP2GM170825 | De novo design of allosteric proteins that sense and respond to small molecules | 000 | 1 | NIH | 8/25/2026 | $845,500 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K08CA308868 | Dissecting Differentiation and Immune Niches in Liposarcoma for Therapeutic Discovery | 000 | 1 | NIH | 9/14/2026 | $288,006 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA303628 | Novel functions of cell cycle proteins in G1/S phase progression and in cancer | 000 | 1 | NIH | 8/13/2026 | $606,749 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | OT2CA319961 | ILLUMINE - Exploiting the Dark Proteome to fight cancer | 001 | 1 | NIH | 9/15/2026 | $265,329 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | OT2CA319961 | ILLUMINE - Exploiting the Dark Proteome to fight cancer | 000 | 1 | NIH | 8/5/2026 | $1,156,827 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K99CA307630 | Establishing Ethical Standards for Informed Consent and Counseling for Multi-Cancer Early Detection Testing | 000 | 1 | NIH | 4/21/2026 | $134,919 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA316855 | Family-centered Risk Information and Screening Education to Support Children with Genetic Cancer Risk | 000 | 1 | NIH | 7/29/2026 | $766,699 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K08CA304374 | Characterizing and targeting acquired resistance to menin-KMT2A inhibitors in acute myeloid leukemia. | 000 | 1 | NIH | 8/28/2026 | $233,478 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA303334 | Context-specific pathway dependencies for nuclear envelope proteins in brain cancer | 000 | 1 | NIH | 6/25/2026 | $718,275 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K99CA315559 | Dissecting Transcription Factor-Mediated Chromatin remodeling Complex Activities in Human Cancer | 000 | 1 | NIH | 8/28/2026 | $144,035 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01AG102849 | Rejuvenation of aged hematopoietic stem cells and niche via mitochondrial engineering. | 001 | 1 | NIH | 8/14/2026 | $132,745 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K08CA300921 | Immune Evasion through HLA-E in Diffuse Large B-Cell Lymphoma: Defining Its Regulation and Cellular Interactions | 000 | 2 | NIH | 8/7/2026 | $241,884 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01AG102849 | Rejuvenation of aged hematopoietic stem cells and niche via mitochondrial engineering. | 000 | 1 | NIH | 7/17/2026 | $696,914 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R35GM165595 | Deciphering the mechanistic basis for metabolite control of macrophages | 000 | 1 | NIH | 8/3/2026 | $416,815 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA303051 | IL21R signaling in CD4 T cells converts transient KRASi responses to long term remissions | 000 | 1 | NIH | 8/1/2026 | $643,414 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K00CA294165 | Leveraging informatics to improve communication and outcomes of genetic counseling: The evolving landscape of cancer care. | 001 | 3 | NIH | 8/14/2026 | $1,911 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K00CA294165 | Leveraging informatics to improve communication and outcomes of genetic counseling: The evolving landscape of cancer care. | 000 | 3 | NIH | 7/23/2026 | $97,305 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K99AG097894 | Epigenetic drivers of stem cell fitness in aging hematopoiesis | 000 | 1 | NIH | 8/4/2026 | $130,680 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R21AI200817 | Developmental Potential of IN-TACKs | 000 | 1 | NIH | 5/4/2026 | $267,000 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R34CA308746 | Healing Gardens: Leveraging serious games to deliver accessible pain-CBT and pharmacologic support for patients with advanced cancer managing pain | 000 | 1 | NIH | 7/30/2026 | $340,737 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K99GM157510 | Revealing Cellular Determinants of LINE-1 Retrotransposition Outcomes | 000 | 2 | NIH | 7/29/2026 | $125,000 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F31CA301844 | Unraveling the Mechanisms of Neoantigen Vaccine-Induced Epitope Spreading | 000 | 2 | NIH | 6/10/2026 | $37,114 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U54CA274516 | Radiation Oncology at the Interface of Pediatric Cancer Biology and Data Science | 001 | 4 | NIH | 9/2/2026 | $1,531,447 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01HG014175 | Calling germline and mosaic variants from long genomic and RNA-seq reads | 000 | 2 | NIH | 8/13/2026 | $515,462 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R00CA286805 | Dissecting the Role of Germline Genetics in RAS-Driven Cancers | 000 | 4 | NIH | 9/17/2026 | $187,250 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01DK140171 | Cellular and Biochemical Pathways of Adipose Metabolism and Thermogenesis | 000 | 2 | NIH | 4/28/2026 | $844,198 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F31AI191729 | Deciphering the mechanisms regulating itaconate production and signaling in macrophages | 000 | 2 | NIH | 8/11/2026 | $48,521 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01DK142741 | Structural Basis of Thermogenic Mitochondrial Respiratory Complexes Assembly | 000 | 2 | NIH | 4/6/2026 | $813,511 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F32CA306146 | Elucidating the role of PATZ1 in MYCN-amplified neuroblastoma | 000 | 2 | NIH | 8/6/2026 | $81,580 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA269285 | Cyclin C-CDK8/19 kinases in development and in cancer | 000 | 5 | NIH | 4/17/2026 | $525,969 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K99CA300495 | Dissecting the impact of tumor-immune spatial interactions in mismatch-repair stratified colorectal cancers | 000 | 2 | NIH | 7/16/2026 | $170,641 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F32CA298459 | Interrogating the role of IFNgamma in promoting metastasis and immune evasion of triple negative breast cancer | 000 | 2 | NIH | 7/31/2026 | $79,348 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA279391 | Merkel cell polyomavirus HLA class I epitopes for generating therapeutic T cell-based cancer immunotherapy | 001 | 3 | NIH | 4/16/2026 | $72,700 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA279391 | Merkel cell polyomavirus HLA class I epitopes for generating therapeutic T cell-based cancer immunotherapy | 000 | 3 | NIH | 1/15/2026 | $654,298 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K00CA284254 | Defining Therapeutically Targetable Regulators of Tumor-Intrinsic Immune Suppression in Glioblastoma | 000 | 4 | NIH | 1/13/2026 | $92,813 |
|
